The largest holder of Elanco Animal Health stock is Dodge & Cox, with 67.4 million shares (13.49% of the company), worth about $1.61 billion as of September 25, 2026. The 10 largest holders together own 69.0%.
In Q2 2026, 537 institutional holdings reports listed shares worth $14.50 billion.
Insiders reported 66 transactions in the last two years: no sales and 6 purchases. The newest one on file is from April 1, 2026 (De Brabander Ellen, Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through April 1, 2026.

2026Q2
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Dodge & Cox | 67.4 million | 13.49% | $1.6B |
| Fidelity Management & Research Co. LLC | 56.9 million | 11.40% | $1.4B |
| BlackRock Advisors LLC | 46.7 million | 9.34% | $1.1B |
| PRIMECAP Management Co. | 45.4 million | 9.10% | $1.1B |
| T. Rowe Price Investment Management, Inc. | 28.8 million | 5.75% | $688.0M |
| DFA Australia Ltd. | 24.6 million | 4.92% | $589.0M |
| Vanguard Portfolio Management LLC | 22.7 million | 4.54% | $542.0M |
| Vanguard Capital Management LLC | 22.6 million | 4.53% | $541.0M |
| State Street Corporation | 16.1 million | 3.21% | $384.0M |
| Winslow Capital Management LLC | 13.5 million | 2.70% | $323.0M |
As of September 25, 2026.
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 537 | – | $14.5B |
| Q1 2026 | 533 | – | $13.0B |
| Q4 2025 | 511 | – | $12.7B |
| Q3 2025 | 432 | – | $11.5B |
| Q2 2025 | 392 | 539.0 million | $7.7B |
| Q1 2025 | 388 | 500.0 million | $5.3B |
| Q4 2024 | 421 | 490.0 million | $5.9B |
| Q3 2024 | 426 | 493.0 million | $7.2B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| De Brabander Ellen | Apr 1, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Simmons Jeffrey N. | Feb 27, 2026 | Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Bettington Timothy J | Feb 27, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Correia De Simas Jose Manuel | Feb 27, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| De Brabander Ellen | Feb 27, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Modi Rajeev A | Feb 27, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Mc-Ardle Gerald | Feb 27, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| O'Neill Shiv | Feb 27, 2026 | General Counsel | Stock Award(Grant) at price 0.00 per share. | – |
| Vanhimbergen Robert M | Feb 27, 2026 | Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Cabral Ramiro Martin | Feb 27, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Kinard David S | Feb 27, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Meer James M | Feb 27, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
Newest 12 of 66 insider transactions in the last two years.
Dodge & Cox, with 13.49% of the company (as of September 25, 2026). Next: Fidelity Management & Research Co. LLC (11.40%) and BlackRock Advisors LLC (9.34%).
537 institutional holdings reports listed Elanco Animal Health shares in Q2 2026 worth $14.50 billion.
In the last two years insiders reported no sales and 6 purchases (66 transactions in all); the newest on file is from April 1, 2026.